| SC 13D/A | 2024-02-14 | LSV Associates, LLC | ALX ONCOLOGY HOLDINGS INC | 1,366,530 | 2.7% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | ALX ONCOLOGY HOLDINGS INC | 2,255,000 | 4.5% | EDGAR |
| SC 13G/A | 2024-02-14 | Redmile Group, LLC | ALX ONCOLOGY HOLDINGS INC | 4,909,264 | 9.6% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | ALX ONCOLOGY HOLDINGS INC | 7,472,821 | 15.0% | EDGAR |
| SC 13D/A | 2023-12-20 | LSV Associates, LLC | ALX ONCOLOGY HOLDINGS INC | 1,950,004 | 3.9% | EDGAR |
| SC 13G | 2023-10-16 | Redmile Group, LLC | ALX ONCOLOGY HOLDINGS INC | 4,991,545 | 9.6% | EDGAR |
| SC 13G | 2023-10-13 | Cormorant Asset Management, LP | ALX ONCOLOGY HOLDINGS INC | 2,630,000 | - | EDGAR |
| SC 13G | 2023-02-14 | ORBIMED ADVISORS LLC | ALX ONCOLOGY HOLDINGS INC | 2,266,000 | 5.6% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | ALX ONCOLOGY HOLDINGS INC | 6,113,428 | 15.0% | EDGAR |
| SC 13G/A | 2022-08-10 | FMR LLC | ALX ONCOLOGY HOLDINGS INC | 4,280,516 | 10.5% | EDGAR |
| SC 13G/A | 2022-06-10 | WELLINGTON MANAGEMENT GROUP LLP | ALX ONCOLOGY HOLDINGS INC | 1,128,101 | 2.8% | EDGAR |
| SC 13G | 2022-02-09 | FMR LLC | ALX ONCOLOGY HOLDINGS INC | 2,592,939 | 6.4% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | ALX ONCOLOGY HOLDINGS INC | 3,728,330 | 9.2% | EDGAR |
| SC 13G | 2021-09-10 | WELLINGTON MANAGEMENT GROUP LLP | ALX ONCOLOGY HOLDINGS INC | 4,205,127 | 10.4% | EDGAR |
| SC 13D/A | 2021-06-15 | Logos Global Management LP | ALX ONCOLOGY HOLDINGS INC | 3,156,981 | 7.9% | EDGAR |
| SC 13D | 2020-10-01 | venBio Global Strategic Fund II L.P. | ALX ONCOLOGY HOLDINGS INC | 4,431,600 | 12.1% | EDGAR |
| SC 13D | 2020-08-26 | Logos Global Management LP | ALX ONCOLOGY HOLDINGS INC | 3,080,901 | 8.4% | EDGAR |
| SC 13D | 2020-07-31 | LSV Associates, LLC | ALX ONCOLOGY HOLDINGS INC | 2,268,087 | 6.2% | EDGAR |
| SC 13G | 2020-07-29 | Vivo Capital IX, LLC | ALX ONCOLOGY HOLDINGS INC | 4,034,522 | 11.1% | EDGAR |